Xamoterol hemifumarate

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562251

CAS#: 73210-73-8

Description: Xamoterol hemifumarate is a third generation specific adrenergic ß1 receptor partial agonist.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-06-05. Prices are subject to change without notice.

Xamoterol hemifumarate is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 562251
Name: Xamoterol hemifumarate
CAS#: 73210-73-8
Chemical Formula: C36H54N6O14
Exact Mass:
Molecular Weight: 794.85
Elemental Analysis: C, 54.40; H, 6.85; N, 10.57; O, 28.18

Synonym: Xamoterol hemifumarate; ICI-118587 hemioxalate; ICI 118587 hemioxalate; ICI118587 hemioxalate;

IUPAC/Chemical Name: (R)-N-(2-((2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino)ethyl)morpholine-4-carboxamide hemifumarate


InChi Code: InChI=1S/2C16H25N3O5.C4H4O4/c2*20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19;5-3(6)1-2-4(7)8/h2*1-4,14,17,20-21H,5-12H2,(H,18,22);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*14-;/m11./s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Cruickshank JM. Beta-blockers and heart failure. Indian Heart J. 2010 Mar-Apr;62(2):101-10. Review. PubMed PMID: 21180298.

2: Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27. Epub 2007 Apr 12. Review. PubMed PMID: 17433471.

3: Tsoi C, Swedmark S. Sulfation in dog. Curr Drug Metab. 2005 Jun;6(3):275-85. Review. PubMed PMID: 15975044.

4: Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev. 2002;(1):CD002992. Review. Update in: Cochrane Database Syst Rev. 2002;(4):CD002992. PubMed PMID: 11869646.

5: van Veldhuisen DJ, Poole-Wilson PA. The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure. Int J Cardiol. 2001 Aug;80(1):19-27. Review. PubMed PMID: 11532543.

6: Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blocker use in patients with reversible airway disease. Cochrane Database Syst Rev. 2001;(2):CD002992. Review. Update in: Cochrane Database Syst Rev. 2002;(1):CD002992. PubMed PMID: 11406056.

7: Febo O, Cobelli F. [Exercise test in the evaluation of the efficacy of drug therapy]. Ital Heart J Suppl. 2000 Mar;1(3):393-9. Review. Italian. PubMed PMID: 10815269.

8: Carson PE. Beta-blocker therapy in heart failure: pathophysiology and clinical results. Curr Probl Cardiol. 1999 Jul;24(7):421-60. Review. PubMed PMID: 10403092.

9: Bonarjee VV, Dickstein K. Novel drugs and current therapeutic approaches in the treatment of heart failure. Drugs. 1996 Mar;51(3):347-58. Review. PubMed PMID: 8882374.

10: Shah R. CPMP note for guidance: clinical trials on the medicinal products in the treatment of cardiac failure. Methods Find Exp Clin Pharmacol. 1996;18 Suppl C:31-3. Review. PubMed PMID: 9003573.

11: Cruickshank JM. The xamoterol experience in the treatment of heart failure. Am J Cardiol. 1993 Mar 25;71(9):61C-64C. Review. PubMed PMID: 8465800.

12: Fowler MB. Controlled trials with beta blockers in heart failure: metoprolol as the prototype. Am J Cardiol. 1993 Mar 25;71(9):45C-53C. Review. PubMed PMID: 8096675.

13: Sørensen EV. Xamoterol--a beta-1-adrenoceptor partial agonist. Pharmacology and clinical use. Dan Med Bull. 1993 Mar;40(1):111-21. Review. PubMed PMID: 8472594.

14: MacFadyen RJ. Role of the circulating and tissue-based renin-angiotensin system in the development of heart failure: implications for therapy. Cardiology. 1993;83(1-2):38-48. Review. PubMed PMID: 8261485.

15: Widimský J, Cihák R. [Can pharmacotherapy in heart failure affect mortality?]. Vnitr Lek. 1992 Mar;38(3):209-19. Review. Czech. PubMed PMID: 1595210.

16: Hayashida W, Kumada T, Kawai C. [New oral drugs for the treatment of congestive heart failure]. Nihon Rinsho. 1992 Feb;50(2):413-9. Review. Japanese. PubMed PMID: 1319514.

17: Widimský J. Can pharmacological therapy influence the mortality of chronic congestive heart failure? Cor Vasa. 1992;34(1):15-30. Review. PubMed PMID: 1288941.

18: Johnson JA. Diastolic dysfunction in congestive heart failure. Clin Pharm. 1991 Nov;10(11):850-61. Review. PubMed PMID: 1794221.

19: Waller DG. Effect of drug treatment on quality of life in mild to moderate heart failure. Drug Saf. 1991 Jul-Aug;6(4):241-6. Review. PubMed PMID: 1888440.

20: Xamoterol--more trouble than it's worth? Drug Ther Bull. 1990 Jul 9;28(14):53-4. Review. PubMed PMID: 1983395.